Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Candidate disease progression biomarkers in AD

ABSTRACT: Cross-sectional and longitudinal Analysis of CSF from controls and cases with AD

INSTRUMENT(S): LTQ FT

ORGANISM(S): Homo Sapiens (ncbitaxon:9606)

SUBMITTER: Hendrickson, RC

PROVIDER: MSV000079192 | MassIVE | Wed Jul 15 09:30:00 BST 2015

SECONDARY ACCESSION(S): PXD002546

REPOSITORIES: MassIVE

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Publications

High Resolution Discovery Proteomics Reveals Candidate Disease Progression Markers of Alzheimer's Disease in Human Cerebrospinal Fluid.

Hendrickson Ronald C RC Lee Anita Y H AY Song Qinghua Q Liaw Andy A Wiener Matt M Paweletz Cloud P CP Seeburger Jeffrey L JL Li Jenny J Meng Fanyu F Deyanova Ekaterina G EG Mazur Matthew T MT Settlage Robert E RE Zhao Xuemei X Southwick Katie K Du Yi Y Holder Dan D Sachs Jeffrey R JR Laterza Omar F OF Dallob Aimee A Chappell Derek L DL Snyder Karen K Modur Vijay V King Elizabeth E Joachim Catharine C Bondarenko Andrey Y AY Shearman Mark M Soper Keith A KA Smith A David AD Potter William Z WZ Koblan Ken S KS Sachs Alan B AB Yates Nathan A NA

PloS one 20150813 8

Disease modifying treatments for Alzheimer's disease (AD) constitute a major goal in medicine. Current trends suggest that biomarkers reflective of AD neuropathology and modifiable by treatment would provide supportive evidence for disease modification. Nevertheless, a lack of quantitative tools to assess disease modifying treatment effects remains a major hurdle. Cerebrospinal fluid (CSF) biochemical markers such as total tau, p-tau and Ab42 are well established markers of AD; however, global q ...[more]

PMID: 26270474

Similar Datasets

TLDA miRNA Screen for Candidate AD Biomarkers in CSF from Living Donors

Project description:Identify candidate miRNA biomarkers for AD in CSF.

2022-09-03 | GSE212558 | GEO

Validation Study for Candidate AD miRNA Biomarkers in Human CSF

Project description:We used an independent cohort of patient CSF samples from living donors obtained from the Shiley-Marcos Alzheimer's Disease Research Center at the Univ of CA, San Diego to validate the expression of 36 candidate AD miRNA biomarkers. The miRNAs were quantified on custom Taqman Low Density miRNA Arrays from ThermoFisher Scientific; miRNA probes were consistent to those used in the UH2 discovery arrays.

2022-09-03 | GSE212623 | GEO

Ventriculomics analyses of autopsy AD tissue

Project description:Very little studies have explored the role played by the specialized choroid plexus epithelial cells and the ependymal cells that line the ventricles. In normal and pathological (AD) ageing, reports of alterations in the blood brain CSF barrier (BCSFB) integrity and membrane transporters, accompanied by deficiencies in CSF production and an enlarged ventricular volume have been documented. The molecular sequelae of events driving these age-related pathological changes remains elusive. Given the pivotal role of the ventricular system in normal brain physiology, in this study we proposed to explore their contributing role towards AD pathogenesis. To address this, we used our state-of-the-art proteomic platform, a liquid chromatography/mass spectrometry (LC-MS) approach coupled with Tandem Mass Tag labeling technology to conduct a detailed characterization and assessment of molecular changes in protein expression levels from isolated tissue from the walls of the ventricles in autopsy AD cases, and two groups of age-matched control cases (non-agenarian’s with no AD pathology, and those with no clinical AD diagnosis but significant amyloid pathology and Braak staging).

2021-09-08 | PXD012059 | Pride

Co-expression network analysis of frontal cortex during the progression of Alzheimer’s disease

Project description:Using WGCNA and enrichment analyses to identify pathway level differences between individuals with no cognitive impairment, mild cognitive impairment, and Alzheimer’s disease. Frozen frontal cortex (BA10) tissue from NCI, MCI, and mild/moderate AD cases (n = 12/group) representing both genders was acquired postmortem from participants in the Rush Religious Orders Study, a longitudinal clinical pathologic study of aging and AD in elderly Catholic clergy

2021-10-15 | GSE185909 | GEO

Ad vectors in C3KO mice

Project description:Replication-deficient adenovirus (Ad) type 5 capsids induce potent host innate immune responses. One system pivotal in host innate immune defense is the complement system. Intriguingly, excessive or inappropriate complement activation can result in extreme tissue damage and systemic inflammatory responses similar to those noted immediately after high dose systemic Ad vector injections. To determine if the complement system has a significant role in intensifying Ad-associated acute toxicities, we compared complement deficient (C3-knockout (KO)) mice responses to those of wild type (WT) mice following systemic challenge with Ad vectors. We noted not only thrombocytopenia and rapid increases in plasma IL-6, IFN-γ, TNF-α, and IL-12 levels previously reported after high dose Ad injections into WT mice, but also induction of cytokines IL-2, IL-4, IL-5 and IL-10, G-CSF and GM-CSF, and chemokines KC (CXCL1) and MIP-1. This expanded innate response “profile” was significantly blunted in Ad injected C3-KO mice, with a near complete avoidance of thrombocytopenia. Further validation for complement’s critical role in perturbing these innate responses against Ad were noted after comparison of gene specific RNA transcription levels in C3-KO to WT mice livers. Finally, these disparities were not attributed to a diminished ability of the Ad vectors to transduce C3-KO mice hepatocytes. These results suggest that Ad capsid interaction with the mammalian complement system may exacerbate the toxicity of systemic Ad injections, and thus represents a future target for manipulation in efforts to improve the efficacy and safety profile of Ad mediated gene delivery. Keywords: adenovirus, complement system, time course, innate immune response, toxicity

2006-02-15 | GSE4128 | GEO

Dementia Comparison: VaD vs. AD vs. Controls

Project description:Gene expression profiling was performed on frontal and temporal cortex from vascular dementia (VaD), Alzheimer's disease (AD), and non-demented controls (Control) obtained from the University of Michigan Brain Bank. Controls and AD cases had no infarcts in the autopsied hemisphere. Vascular dementia cases had low Braak staging.

2019-04-23 | GSE122063 | GEO

Methylation disorder in CLL

Project description:We performed RRBS and WGBS on primary human chronic lymphocytic leukemia and normal healthy donor B cell samples Due to patient privacy concerns, the raw data is being made available via controlled access in dbGaP (http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000435.v1.p1). cross-sectional/longitudinal

2015-01-01 | E-GEOD-58889 | biostudies-arrayexpress

Profilling of aggregated proteome in human control and AD cases

Project description:Analyzing and comparing proteome profiling between human control and AD cases will be beneficial to understand the molecular changes of insoluble fractions of AD cases.

2022-08-12 | PXD031587 | Pride

The power of many: Combining published datasets to identify Alzheimer’s disease biomarkers in cerebrospinal fluid

Project description:This manuscript describes methodology for the meta-analysis of published proteomics datasets from multiple publications to mine for cerebrospinal fluid (CSF)-based diagnostic biomarkers for Alzheimer’s disease (AD).The identified biomarkers are then validated in an independent cohort analyzed in house and two additional published large datasets. Specifically, the published data was mined from 6 independent and a 7th in-house acquired CSF proteomic datasets resulting in a meta-cohort with 73 AD cases and 77 controls. In-depth data analysis revealed 35 CSF biomarker candidates, many of which are associated with brain glucose homeostasis, which is described to be dysregulated in AD. Next, the list of identified biomarker candidates were then validated in a 2-pronged approach using i) an independent cohort analyzed in house, and ii) two recently published independent large scale datasets comprising in total more than 500 samples. The resulting biomarker panel consisting of three glycolytic enzymes was found to discriminate AD from controls. To our knowledge, this is the first study that described the mining and systematic re-analysis of previously published liquid chromatography mass spectrometry-based proteomics data to identify and validate biomarkers in general and CSF biomarkers for AD in particular. While the presented study focused on AD, the presented workflow can be applied to any disease for which published datasets are available.

2023-02-16 | PXD022649 | Pride

2-year Longitudinal Analyses of Peripheral Blood RNA in Huntington's Disease gene-positive and control subjects

Project description:Samples collected in the course of the TRACK HD study and used to analyse association between gene expression in blood and symptomatic progression of Huntington's disease Longitudinal analysis of UHDRS TMS versus gene expression in individual subjects followed by cross-sectional comparisons across phenotype groups at each timepoint

2020-09-23 | GSE135589 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data